Literature DB >> 7620299

Contribution of alpha- and beta- adrenoceptors and neuropeptide-Y to autonomic dysreflexia.

D Santajuliana1, Z Zukowska-Grojec, J W Osborn.   

Abstract

Modest increases in urinary bladder pressure result in acute hypertensive episodes in humans with spinal cord lesions above T5. The underlying mechanisms of this condition, referred to as autonomic dysreflexia, are not well understood. The aim of this study was to characterize the contribution of alpha- and beta-adrenoceptors as well as circulating neuropeptide-Y (NPY) to the pressor response to bladder distension in conscious cervical spinal rats. Rats were chronically instrumented with arterial and venous catheters. After 2-3 days, a complete spinal transection (C7) was performed, and the urinary bladder was catheterized: 24 h later, mean arterial pressure (MAP) responses to 5 min bladder distensions (+40) were measured under control conditions and after administration of specific autonomic antagonists. To assess the contribution of alpha and beta adrenergic mechanisms the alpha antagonist prazosin (0.45 mg/kg i.v.) and beta antagonist, propranolol (4 mg/kg i.v.), were administered individually or together. Blood samples were taken before, during and after bladder distension for determination of plasma NPY by radioimmunoassay. The pressor response to bladder distension was approximately 30 mmHg under control conditions. The response was attenuated (-38%), but not abolished, by prazosin. A similar attenuation (-41%) was observed with propranolol. There were no changes in plasma NPY in response to bladder distension. Finally, the pressor response was completely abolished by combined alpha- and beta-adrenergic blockade. These results suggest that autonomic dysreflexia is mediated exclusively by adrenergic receptors in the spinal rat. Moreover, both alpha and beta adrenergic receptors contribute to the pressor response induced by bladder distension in the conscious cervical spinal rat.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7620299     DOI: 10.1007/BF01827469

Source DB:  PubMed          Journal:  Clin Auton Res        ISSN: 0959-9851            Impact factor:   4.435


  24 in total

1.  The acutely affected abdomen in paraplegic spinal cord injury patients.

Authors:  L A Neumayer; D A Bull; J D Mohr; C W Putnam
Journal:  Ann Surg       Date:  1990-11       Impact factor: 12.969

Review 2.  The role of neuropeptide Y in cardiovascular regulation.

Authors:  P Walker; E Grouzmann; M Burnier; B Waeber
Journal:  Trends Pharmacol Sci       Date:  1991-03       Impact factor: 14.819

3.  Chronic vascular constrictions and measurements of renal function in conscious rats.

Authors:  M Gellai; H Valtin
Journal:  Kidney Int       Date:  1979-04       Impact factor: 10.612

Review 4.  Autonomic hyperreflexia: a review.

Authors:  B Johnson; R Thomason; V Pallares; M X Sadove
Journal:  Mil Med       Date:  1975-05       Impact factor: 1.437

5.  Incidence and clinical features of autonomic dysreflexia in patients with spinal cord injury.

Authors:  R Lindan; E Joiner; A A Freehafer; C Hazel
Journal:  Paraplegia       Date:  1980-10

6.  Neuropeptide Y is a potent vasoconstrictor and a cardiodepressant in rat.

Authors:  Z Zukowska-Grojec; E S Marks; M Haass
Journal:  Am J Physiol       Date:  1987-11

7.  Autonomic hyperreflexia in spinal cord injury patient during percutaneous nephrolithotomy for renal stone: a case report.

Authors:  C P Chang; M T Chen; L S Chang
Journal:  J Urol       Date:  1991-12       Impact factor: 7.450

8.  Chronic cervical spinal cord injury and autonomic hyperreflexia in rats.

Authors:  J W Osborn; R F Taylor; L P Schramm
Journal:  Am J Physiol       Date:  1990-01

9.  Effects of clonidine, dihydralazine and splanchnic nerve stimulation on the release of neuropeptide Y, MET-enkephalin and catecholamines from dog adrenal medulla.

Authors:  C Damase-Michel; G Tavernier; P Giraud; J L Montastruc; P Montastruc; M A Tran
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-10       Impact factor: 3.000

10.  The effect of terazosin on bladder function in the spinal cord injured patient.

Authors:  S J Swierzewski; E A Gormley; W D Belville; P M Sweetser; J Wan; E J McGuire
Journal:  J Urol       Date:  1994-04       Impact factor: 7.450

View more
  7 in total

1.  Acute administration of AMPA/Kainate blocker combined with delayed transplantation of neural precursors improves lower urinary tract function in spinal injured rats.

Authors:  Takahiko Mitsui; Birgit Neuhuber; Itzhak Fischer
Journal:  Brain Res       Date:  2011-08-22       Impact factor: 3.252

Review 2.  Latest approaches for the treatment of spasticity and autonomic dysreflexia in chronic spinal cord injury.

Authors:  Alexander G Rabchevsky; Patrick H Kitzman
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

3.  Cardiovascular and hormonal responses to food ingestion in humans with spinal cord transection.

Authors:  R R Baliga; A B Catz; L D Watson; D J Short; H L Frankel; C J Mathias
Journal:  Clin Auton Res       Date:  1997-06       Impact factor: 4.435

4.  Spinal cord injury alters purinergic neurotransmission to mesenteric arteries in rats.

Authors:  Sutheera Sangsiri; Hui Xu; Roxanne Fernandes; Greg D Fink; Heidi L Lujan; Stephen E DiCarlo; James J Galligan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-11-27       Impact factor: 4.733

Review 5.  Vascular dysfunctions following spinal cord injury.

Authors:  Constantin Popa; Florian Popa; Valentin Titus Grigorean; Gelu Onose; Aurelia Mihaela Sandu; Mihai Popescu; Gheorghe Burnei; Victor Strambu; Crina Sinescu
Journal:  J Med Life       Date:  2010 Jul-Sep

6.  Spinal cord injury increases the reactivity of rat tail artery to angiotensin II.

Authors:  Hussain Al Dera; James A Brock
Journal:  Front Neurosci       Date:  2015-01-06       Impact factor: 4.677

7.  Purinergic receptor antagonism: A viable strategy for the management of autonomic dysreflexia?

Authors:  Zeljka Minic; Donal S O'Leary; Christian A Reynolds
Journal:  Auton Neurosci       Date:  2020-11-16       Impact factor: 3.145

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.